Skip to main content
This block is broken or missing. You may be missing content or you might need to enable the original module.
Home

Main sub menu

  • Investors
  • Careers
    • Working at Recipharm
    • The Recipharm story
    • Meet our employees
    • Current vacancies
  • Contact
    • Contact us
    • Development services contacts
    • Manufacturing services contacts
    • Locations
      • France
        • Fontaine
        • Kaysersberg
        • Monts
        • Pessac
      • Germany
        • Monheim
        • Wasserburg
        • Zwickau
      • India
        • Bengaluru
        • Karnal / Paonta Sahib
      • Israel
        • Ness Ziona
      • Italy
        • Brescia
        • Lainate
        • Masate
        • Paderno Dugnano
        • Pianezza
      • Portugal
        • Odivelas
        • Queluz
      • Spain
        • Parets
        • Leganés
      • Sweden
        • Höganäs
        • Stockholm city (HQ)
        • Karlskoga
        • Solna
        • Strängnäs
        • Uppsala
        • Uppsala Development
      • UK
        • Cramlington
        • Holmes Chapel
        • Queenborough
        • King’s Lynn
      • USA
        • Research Triangle Park

Main navigation

  • Development
    • Drug substance
    • Drug product
    • Analytical chemistry
    • Clinical trial material (CTM)
  • Manufacturing
    • Solids
    • Semi-solids
    • Liquids
    • Inhalation
    • Injectables
    • Ophthalmics
  • Solutions
    • Recipharm Analytical Solutions™
    • Recipharm Inhalation Solutions™
    • Recipharm Pathway to Clinic®
    • Serialisation
  • Bespak
  • Learn
  • Press & events
    • Press
    • Events
    • Reports
    • Insights
  • Our story
    • Recipharm in brief
    • Business model
    • Sustainability
    • Company history

Press & events

What's happening?

Stay updated on our latest news and events.

Press and Event

  • Press
  • Events
  • Reports
  • Insights
Displaying 61 - 70 of 406

Subscribe

Press

Recipharm announces that Consort Medical applies for delisting

2020.02.06 Read more

Press

Consort Medical becomes part of the Recipharm Group

2020.02.05 Read more

Press

Recipharm declares the offer for Consort Medical wholly unconditional

2020.02.04 Read more

Press

Recipharm publishes no extension and no increase statement and receives Irish competition clearance

2020.01.29 Read more

Press

Correction Statement

2020.01.24 Read more

Press

Recipharm further extends the acceptance period for the offer to acquire Consort Medical and updates on level of acceptance

2020.01.24 Read more

Press

Recipharm acquires shares in Consort Medical

2020.01.22 Read more

Press

Recipharm receives competition clearance from German competition authorities for the offer to acquire Consort Medical

2020.01.14 Read more

Press

Recipharm extends the acceptance period for the offer to acquire Consort Medical and updates on level of acceptance

2020.01.10 Read more

Press

Recipharm partners with Aptahem for formulation of Apta-1 drug candidate

2019.12.17 Read more

Pagination

  • First page « First
  • Previous page ‹ Previous
  • …
  • Page 3
  • Page 4
  • Page 5
  • Page 6
  • Current page 7
  • Page 8
  • Page 9
  • Page 10
  • Page 11
  • …
  • Next page Next ›
  • Last page Last »

Footer menu

  • Privacy policy
  • Cookies
  • Website terms
© 2021 Recipharm AB (publ). All rights reserved Stormfors Digitalbyrå